The dilemma of two innovative therapies for spinal muscular atrophy

New England Journal of Medicine

Volumn 377, Issue 18, 2017, Pages 1786-1787

  Van Der Ploeg, Ans T ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; NUSINERSEN; SURVIVAL MOTOR NEURON PROTEIN 1; SURVIVAL MOTOR NEURON PROTEIN 2;

DRUG EFFICACY; EDITORIAL; EXON SKIPPING; GENE; GENE IDENTIFICATION; GENE MUTATION; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RNA SPLICING; SMN1 GENE; SMN2 GENE; SPINAL MUSCULAR ATROPHY; EXPERIMENTAL THERAPY;

HUMANS; MUSCULAR ATROPHY, SPINAL; THERAPIES, INVESTIGATIONAL;

EID: 85032672902     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1712106     Document Type: Editorial

References (10)

1. Mendell JR, Al-Zaidy S, Shell R, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med 2017;377:1713-22.
2. Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med 2017;377:1723-32.
3. Finkel RS, Chiriboga CA, Vajsar J, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet 2016;388:3017-26.
4. Chiriboga CA, Swoboda KJ, Darras BT, et al. Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy. Neurology 2016;86:890-7.
5. Hoy SM. Nusinersen: first global approval. Drugs 2017;77: 473-9.
6. Aartsma-Rus A. FDA approval of nusinersen for spinal muscular atrophy makes 2016 the year of splice modulating oligonucleotides. Nucleic Acid Ther 2017;27:67-9.
7. Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 2009;27:59-65.
8. Foust KD, Wang X, McGovern VL, et al. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol 2010;28:271-4.
9. Tizzano EF, Finkel RS. Spinal muscular atrophy: a changing phenotype beyond the clinical trials. Neuromuscul Disord 2017; 27:883-9.
10. Hua Y, Sahashi K, Rigo F, et al. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature 2011;478:123-6.